Fig. 3
Administration of anti-CXCL13 antibody reduces infarct volume and inhibits the infiltration of TFH cells into the brain following tMCAO. a Experimental design for administration of IgG2a and anti-CXCL13 antibody (100 μg) i.p. b Representative cresyl violet images to assess ischemic brain damage at 24 h tMCAO in IgG2a-treated and anti-CXCL13 antibody (100 μg)-treated mice. c Quantification of infarct volumes (mm3) at 24 h tMCAO in IgG2a-treated and CXCL13 antibody-treated mice (n = 10). d Representative flow cytometry gating of CD4+ ICOS-1+ and subsequent CXCR5+ IL-21+ cells from the ipsilateral brain of IgG2a isotype control-treated or anti-CXCL13 antibody-treated mice at 24 h following tMCAO. e–g Quantification of CD4+ T cells (e), % of CD4 T cells+ for ICOS-1 (f), and % of CD4+ ICOS-1+ T cells+ for CXCR5+ and IL-21+ (g) from IgG2a isotype control-treated and anti-CXCL13 antibody-treated mice at 24 h tMCAO. (n = 6) Data are combined from three independent experiments. Data represent mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Student’s t test with Mann–Whitney U test (c, e–g)